Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
J Pharmacol Exp Ther. 2019 Sep;370(3):570-580. doi: 10.1124/jpet.119.257113. Epub 2019 Mar 5.
The use of drug delivery systems (DDS) is an attractive approach to facilitate uptake of therapeutic agents at the desired site of action, particularly when free drug has poor pharmacokinetics/biodistribution (PK/BD) or significant off-site toxicities. Successful translation of DDS into the clinic is dependent on a thorough understanding of the in vivo behavior of the carrier, which has, for the most part, been an elusive goal. This is, at least in part, due to significant differences in the mechanisms controlling pharmacokinetics for classic drugs and DDSs. In this review, we summarize the key physiologic mechanisms controlling the in vivo behavior of DDS, compare and contrast this with classic drugs, and describe engineering strategies designed to improve DDS PK/BD. In addition, we describe quantitative approaches that could be useful for describing PK/BD of DDS, as well as critical steps between tissue uptake and pharmacologic effect.
药物传递系统(DDS)的应用是一种很有吸引力的方法,可以促进治疗剂在所需作用部位的吸收,特别是当游离药物的药代动力学/生物分布(PK/BD)较差或具有明显的非靶位毒性时。DDS 要成功转化为临床应用,取决于对载体体内行为的深入了解,而这在很大程度上一直是一个难以实现的目标。这至少部分是由于控制经典药物和 DDS 的药代动力学的机制存在显著差异。在这篇综述中,我们总结了控制 DDS 体内行为的关键生理机制,将其与经典药物进行了比较和对比,并描述了旨在改善 DDS PK/BD 的工程策略。此外,我们还描述了定量方法,这些方法可能有助于描述 DDS 的 PK/BD,以及组织摄取和药理效应之间的关键步骤。